Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of Cellectar’s CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting
April 16, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., April 16, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer
April 04, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., April 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma
April 03, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., April 03, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles
March 27, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Reports 2017 Financial Results and Provides a Corporate Update
March 21, 2018 16:10 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 21, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma
March 19, 2018 08:05 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 19, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018
March 19, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 19, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131
March 15, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 15, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Phase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology
March 06, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 06, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Biosciences to Present at Upcoming March Conferences
March 05, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 05, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...